AD/PD 2026: Targeting Toxic Proteins in Alzheimer’s Drug Development
In Alzheimer’s disease, toxic proteins such as tau accumulate as clearance declines. In this MEDtalk from the AD/PD 2026 Conference, Lisha Wang, Assistant Professor at Karolinska Institutet in Stockholm, presents a project developing novel small molecules that promote targeted degradation of tau by engaging the brain’s clearance machinery.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in








